Valoctocogene Roxaparvovec Evaluated in Severe Hemophilia A
FRIDAY, March 18, 2022 -- For men with severe hemophilia A, treatment with valoctocogene roxaparvovec, an adeno-associated virus 5-based gene-therapy vector, yields a significant increase in factor VIII activity, with a reduction in treated bleeding...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Adenoviruses | Bleeding | Gene Therapy | Genetics | Haemophilia | Hemophilia | Pharmaceuticals